Depression screening for patients with acne in the United States compared to other skin diseases, 2005 to 2016 - 11/01/21
Doi : 10.1016/j.jaad.2020.09.082
Nishadh Sutaria, BS a, Jordan R. Pollock, BS a, b, Shawn G. Kwatra, MD a, ⁎ 
a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Department of Dermatology, Mayo Clinic Alix School of Medicine, Scottsdale, Arizona
∗Correspondence to: Shawn G. Kwatra, MD, Cancer Research Building II, Suite 206, Johns Hopkins University School of Medicine, 1550 Orleans St, Baltimore, MD 21231Cancer Research Building IISuite 206Johns Hopkins University School of Medicine1550 Orleans StBaltimoreMD21231
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr. Kwatra is an advisory board member for Pfizer, Regeneron Pharmaceuticals, and Menlo Therapeutics. Authors Sutaria and Pollock have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. e105-e106 - février 2021 Retour au numéro
Article précédent
- COVID-19 compels closer scrutiny of disparities in dermatology
- Laurie A. Temiz, Lynn McKinley-Grant, Donald A. Glass, Valerie M. Harvey
- Reply to “Depression screening for patients with acne in the United States compared to other skin diseases, 2005 to 2016”
- Matthew T. Taylor, John S. Barbieri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?